Link between high-affinity adenosine concentrative nucleoside transporter-2 (CNT2) and energy metabolism in intestinal and liver parenchymal cells.
Concentrative nucleoside transporter 2 (CNT2) is a high-affinity adenosine transporter that may play physiological roles beyond nucleoside salvage. Previous reports relate CNT2 function to modulation of purinergic signaling and energy metabolism in intestinal and liver parenchymal cells (Duflot et al., 2004, Mol Cell Biol 24:2710-2719; Aymerich et al., 2006, J Cell Sci 119:1612-1621). In the present study, to further examine the link between CNT2 and energy metabolism, CNT2 protein partners were identified using the bacterial two-hybrid and GST pull-down approaches. The N-terminal segment of CNT2 was used as bait, since proteins lacking this domain display impaired plasma membrane insertion and intracellular retention. Glucose-regulated protein 58 (GRP58) was identified as a potential rCNT2 partner in pull-down experiments. Two-hybrid screening performed against a liver human cDNA library led to the identification of aldolase B as another hCNT2 partner. Aldolase B-RFP and endogenous GRP58 separately co-localized with CNT2 in HeLa cells transfected with YFPrCNT2. CNT2 interaction with GRP58 was validated using co-immunoprecipitation experiments. In HeLa cells, fluorescence resonance energy transfer (FRET) efficiency increased upon fructose addition, consistent with a transient interaction between aldolase B and the transporter. The physiological basis for in vivo interactions was derived from experiments in which GRP58 was inhibited or overexpressed and aldolase B activity stimulated towards glycolysis. GRP58 appeared to be a negative effector of CNT2 function, whereas aldolase B flux modulated CNT2 activity via a mechanism involving acquisition of higher affinity for its substrates. These findings support the theory that CNT2 plays roles other than salvage and establishes links with energy metabolism.
Huber-Ruano
Isabel
I
Departament de Bioquímica i Biologia Molecular, Institut de Biomedicina, Universitat de Barcelona and CIBER EHD, Barcelona, Spain.
Pinilla-Macua
Itziar
I
Torres
Gonzalo
G
Casado
F Javier
FJ
Pastor-Anglada
Marçal
M
D000818:Animals; D001414:Bacitracin / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000502:physiology*; D005634:Fructose-Bisphosphate Aldolase / Q000235:genetics / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D007422:Intestines / Q000166:cytology*; D008099:Liver / Q000166:cytology*; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D019704:Protein Disulfide-Isomerases / Q000235:genetics / Q000378:metabolism; D051381:Rats; D014162:Transfection
D026901:Membrane Transport Proteins; C065171:cif nucleoside transporter; D001414:Bacitracin; D005634:Fructose-Bisphosphate Aldolase; D019704:Protein Disulfide-Isomerases; C085868:PDIA3 protein, human; D005947:Glucose